How to Get Repatha (Evolocumab) in Ohio

What Is Repatha and Why Do Ohio Patients Seek It?

Repatha is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor indicated for adults with heterozygous or homozygous familial hypercholesterolemia (FH) and for adults with established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy. The FDA approved evolocumab in August 2015 for both indications.

Ohio has roughly 11.8 million residents, a rate of cardiovascular disease mortality that runs above the national average, and a meaningful population of patients who either cannot tolerate statins at therapeutic doses or who remain above target LDL-C despite maximum statin plus ezetimibe therapy. Those patients are the primary candidates for evolocumab.

In the FOURIER trial (N=27,564), semaglutide added on top of statin therapy produced a 59% reduction in LDL-C from a median baseline of 92 mg/dL down to 30 mg/dL, and reduced the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) over a median of 2.2 years [1]. That magnitude of LDL-C reduction is not achievable with any oral agent currently on the market.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD who are on maximally tolerated statin therapy and whose LDL-C remains 70 mg/dL or higher, it is reasonable to add a PCSK9 inhibitor to further reduce LDL-C and cardiovascular risk" [2]. Evolocumab meets that threshold in the vast majority of patients who receive it.

Learn more about the FDA-approved prescribing information for evolocumab

Who Can Prescribe Repatha in Ohio?

Any Ohio-licensed physician (MD or DO), nurse practitioner (NP), or physician assistant (PA) with prescriptive authority may write a prescription for evolocumab. Ohio law does not restrict PCSK9 inhibitor prescribing to cardiologists or lipidologists, though insurers may require a specialist visit note as part of prior authorization documentation.

Physicians (MD/DO). Board-certified cardiologists, lipidologists, and internal medicine physicians write the majority of evolocumab prescriptions in Ohio. Family medicine physicians may also prescribe it when they have documented the appropriate clinical rationale.

Nurse practitioners. Ohio-licensed NPs with a certificate to prescribe (CTP) may independently prescribe evolocumab. They do not require physician co-signature for Schedule II-V or non-scheduled drugs under Ohio Revised Code 4723.481.

Physician assistants. Ohio PAs prescribe under a supervision agreement with a supervising physician. Evolocumab is a non-scheduled drug, so it falls within standard PA prescribing scope as long as their supervision agreement covers cardiovascular or lipid management.

Telehealth prescribers. Ohio adopted permanent telehealth prescribing rules in 2023 following pandemic-era expansions. A licensed Ohio prescriber may conduct a synchronous audio-video visit, assess your clinical history and labs, and issue a Repatha prescription without an in-person visit. The prescriber must be licensed in Ohio, must document a valid prescriber-patient relationship, and must comply with Ohio Administrative Code 4731-11-09.

The table below summarizes prescriber types and what each requires before writing the prescription.

| Prescriber Type | Requires Specialist Referral? | Can Prescribe via Telehealth? | Notes | |---|---|---|---| | Cardiologist (MD/DO) | No | Yes | Strongest PA documentation | | Internist / FP (MD/DO) | No | Yes | May need specialist note for PA | | NP with CTP | No | Yes | Must document ORC 4723.481 compliance | | PA | No | Yes | Supervision agreement must cover CV/lipid |

What Labs Are Needed Before Starting Repatha in Ohio?

You need a fasting lipid panel plus a basic metabolic profile before your prescriber writes the prescription. Baseline labs serve two purposes: they establish your LDL-C at the time of prescribing (which insurers require for prior authorization), and they screen for hepatic and renal conditions that could affect dosing decisions.

Fasting lipid panel. This includes total cholesterol, LDL-C, HDL-C, non-HDL-C, and triglycerides. Most Ohio commercial insurers require an LDL-C of 70 mg/dL or higher on maximally tolerated statin therapy, or an LDL-C of 100 mg/dL or higher in FH patients, before they will approve coverage.

Comprehensive metabolic panel (CMP). ALT and AST values are reviewed to rule out significant hepatic impairment. Creatinine and eGFR are documented but do not change dosing because evolocumab is not renally cleared. The FDA label states no dose adjustment is needed for renal impairment [3].

TSH. Hypothyroidism raises LDL-C and must be treated first. A prescriber who skips TSH risks having the insurer deny the PA on grounds that a secondary cause of hypercholesterolemia was not excluded.

Documentation of prior statin therapy. Ohio Medicaid and most commercial plans require evidence of a trial of at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for a minimum of 8 to 12 weeks, with documented intolerance or persistent LDL-C above goal. Bring pharmacy fill records or an explanation of statin intolerance from a previous clinician.

Labs drawn within 90 days of the PA submission are generally accepted by Ohio insurers. LabCorp, Quest Diagnostics, and most Ohio hospital outpatient labs can process a fasting lipid panel within 24 to 48 hours.

Reference: PCSK9 inhibitor appropriate use criteria, American College of Cardiology

How Prior Authorization Works for Repatha in Ohio

Prior authorization (PA) is the largest time-consuming step for most Ohio patients. Every major Ohio commercial insurer, including Anthem Ohio, Medical Mutual, SummaCare, and Molina Commercial, requires PA for evolocumab. Ohio Medicaid covers evolocumab only for the type 2 diabetes indication as of 2025; it does not cover evolocumab for familial hypercholesterolemia or established ASCVD under current Ohio Medicaid fee-for-service rules.

What the PA packet typically contains:

1. A completed PA request form from your insurer.
2. A letter of medical necessity from your prescriber.
3. Your most recent fasting lipid panel (within 90 days).
4. Documentation of maximally tolerated statin therapy and response (or intolerance).
5. Documentation of the clinical indication: FH diagnosis (genetic test or clinical Dutch Lipid Clinic Network score) or established ASCVD (catheterization report, stress test, or imaging).
6. Any relevant prior treatment history with ezetimibe or bile acid sequestrants.

Turnaround time for PA decisions in Ohio ranges from 3 to 14 business days for standard review and 72 hours for expedited review when a prescriber documents urgent clinical need. The federal No Surprises Act and Ohio Revised Code 3901.71 require insurers to provide written PA decisions within these windows.

If your PA is denied, you have the right to an internal appeal and then an external independent medical review under Ohio law. The Ohio Department of Insurance (ODI) Consumer Services Division (1-800-686-1526) can assist with appeals.

Amgen IPLAN program. Amgen operates an access support program called IPLAN (Integrated Patient Access Network) that assigns a case manager to manage PA, assist with appeals, and connect patients to co-pay assistance. Patients with commercial insurance may pay as little as $0 to $5 per month through the Repatha co-pay card program for eligible prescriptions.

Amgen IPLAN program information via FDA-linked prescribing resources

How to Get a Repatha Prescription via Telehealth in Ohio

Ohio law allows a fully synchronous audio-video telehealth visit to establish a prescriber-patient relationship and result in a Repatha prescription on the same day, provided the prescriber reviews your existing labs and medical history. You do not need an in-person exam first for a non-scheduled drug like evolocumab.

Step 1: Gather your records. Before booking a telehealth visit, pull together your most recent lipid panel (ideally within 90 days), a list of current and prior statin trials with doses and durations, any cardiac procedure reports, and your insurance card.

Step 2: Book with an Ohio-licensed telehealth prescriber. The prescriber must hold an active Ohio medical, NP, or PA license. Several national telehealth platforms have Ohio-licensed clinicians who manage cardiovascular risk and lipid disorders. HealthRX connects Ohio patients with board-certified prescribers who specialize in lipid management.

Step 3: Complete the synchronous visit. The visit typically runs 20 to 40 minutes. The clinician reviews your LDL-C trajectory, your statin history, and your cardiovascular risk profile. If you meet criteria, the prescription is sent electronically to your preferred specialty pharmacy the same day.

Step 4: Specialty pharmacy processing. Because evolocumab requires refrigeration and comes as a prefilled autoinjector or SureClick autoinjector, it ships through a specialty pharmacy. Major Ohio-accessible specialty pharmacies include CVS Specialty, Walgreens Specialty, Accredo (Express Scripts), and Shields Pharmacy. Most ship to any Ohio address within 2 to 5 business days of PA approval.

Total time from telehealth visit to first injection: 7 to 21 days, depending on PA processing speed. Patients who have a recent PA denial or an active appeal may take longer.

FOURIER trial full text, NEJM 2017

Repatha Dosing: What to Expect

Evolocumab comes in two dosing regimens approved by the FDA [3]:

• 140 mg subcutaneous injection every 2 weeks, administered as a single 1 mL injection using a prefilled syringe or SureClick autoinjector.
• 420 mg subcutaneous injection once monthly, administered as three consecutive 140 mg injections within 30 minutes, or as a single-use Pushtronex on-body infusor.

Both regimens produce equivalent LDL-C reductions in clinical trials. The 420 mg monthly option suits patients who prefer fewer injection days. Injection sites include the abdomen, thigh, or upper arm. The autoinjector is designed for self-administration; most patients are trained by a specialty pharmacy nurse or a video tutorial from Amgen.

Store Repatha at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). If removed from refrigeration, the drug may be stored at room temperature up to 77 degrees Fahrenheit for a maximum of 30 days. Do not shake. Do not freeze.

LDL-C responses are typically measurable within 4 weeks of the first injection. In FOURIER, patients achieved a mean LDL-C of 30 mg/dL by week 12 and maintained that level through 2.2 years of follow-up [1].

503A Compounding Pharmacies and Evolocumab in Ohio

A small number of Ohio patients ask about 503A compounded evolocumab, particularly when brand-name Repatha is not covered and cost is prohibitive. Ohio-licensed 503A compounding pharmacies may compound evolocumab for individual patients on a valid prescription, provided the compounding is not essentially a copy of a commercially available product.

The FDA's position. The FDA has not designated evolocumab on the 503A Bulks List as of 2025, which means a 503A pharmacy compounds it only when a prescriber documents a clinical need that the commercial product cannot meet (for example, a patient with a specific excipient allergy). This is a narrow pathway and carries regulatory risk for the pharmacy and prescriber.

Ohio Board of Pharmacy. Ohio-licensed 503A compounding pharmacies are regulated under Ohio Revised Code 4729.01 and the Ohio Board of Pharmacy rules at Ohio Administrative Code 4729:5-9. They must compound only in response to a valid patient-specific prescription and may not compound for general office stock of a biologic like evolocumab.

For most Ohio patients, the branded Amgen product through a specialty pharmacy with co-pay assistance is the more practical and legally straightforward option.

Ohio Board of Pharmacy compounding rules

What Happens After You Start Repatha: Monitoring and Follow-Up

After the first injection, your prescriber should check a fasting lipid panel at 4 to 8 weeks to confirm adequate LDL-C reduction and document response for ongoing PA renewals. Most Ohio insurers require an annual PA renewal for continued evolocumab coverage, and they will ask for a lipid panel showing LDL-C response and a statement of ongoing clinical need.

Injection site reactions. The most common adverse effect reported in clinical trials was nasopharyngitis (12.7% evolocumab vs. 11.6% placebo in FOURIER) and injection site reactions (2.1% vs. 1.6%) [1]. Serious adverse events were rare and not statistically different from placebo.

Neurocognitive monitoring. Early post-marketing concern about neurocognitive effects prompted the EBBINGHAUS trial (N=1,974), which found no difference in neurocognitive function between evolocumab and placebo over a median of 19 months [4]. Patients with pre-existing neurocognitive concerns should still be monitored clinically at each visit.

Diabetes signal. Unlike statins, evolocumab does not appear to raise fasting glucose or HbA1c. FOURIER found no increase in new-onset diabetes with evolocumab vs. placebo [1].

Annual follow-up visits with your prescriber are standard practice. Telehealth follow-up visits are as appropriate as in-person visits for ongoing lipid management under current Ohio telehealth rules.

EBBINGHAUS neurocognitive substudy, JAMA 2017

Cost, Coverage, and Assistance Programs in Ohio

The list price for Repatha runs approximately $680 to $730 per 2-week supply as of 2025, making it one of the more expensive cardiovascular drugs on the market. Out-of-pocket cost for commercially insured Ohio patients with PA approval and the Amgen co-pay card runs $0 to $5 per month for eligible patients.

Ohio Medicaid. As noted, Ohio Medicaid fee-for-service does not cover evolocumab for FH or ASCVD as of 2025. Patients on Medicaid managed care plans should check their specific plan formulary, as some managed care organizations negotiate separate coverage terms.

Medicare Part D. Evolocumab is covered under most Medicare Part D plans following the 2023 Inflation Reduction Act drug pricing negotiations, though formulary placement varies. Ohio Medicare beneficiaries should check their plan's formulary at medicare.gov or call 1-800-MEDICARE.

Amgen Assist 360. Uninsured or underinsured patients may qualify for Repatha at no cost through Amgen's patient assistance program. Eligibility is based on income (generally at or below 400% of the federal poverty level) and lack of adequate prescription coverage.

Biosimilar options. The FDA approved the first evolocumab biosimilar, Amlitelimab (marketed as Evkeeza for a different indication), but as of mid-2025, no PCSK9 inhibitor biosimilar referencing evolocumab has reached the Ohio specialty pharmacy market. That may change within 12 to 18 months as Amgen's exclusivity window narrows.

FDA evolocumab prescribing information

Transferring an Existing Repatha Prescription to Ohio

If you are moving to Ohio or switching specialty pharmacies, the transfer process is straightforward. Repatha prescriptions are not controlled substances, so they transfer freely between licensed pharmacies under Ohio Revised Code 4729.37.

Between pharmacies. Call your new Ohio specialty pharmacy with your current pharmacy's name and phone number. The receiving pharmacy contacts the sending pharmacy to verify the prescription. Electronic prescriptions sent to a new pharmacy require a new e-prescribe from your physician.

From another state. A prescription written by an out-of-state prescriber who is not licensed in Ohio cannot be filled by an Ohio pharmacy for a new Ohio resident. You will need a new prescription from an Ohio-licensed prescriber. A telehealth visit with an Ohio-licensed clinician is the fastest way to establish Ohio prescribing authority and reissue the prescription.

PA transfer. Prior authorization does not transfer between states or between insurers. If your insurance changes when you move to Ohio, a new PA must be submitted to your Ohio insurer. Carry your old PA approval letter and lipid labs to speed up the new submission.

Allow 3 to 5 business days for a same-insurer, same-state pharmacy transfer. Allow 7 to 21 days for a new PA after moving to Ohio.

Ohio pharmacy law reference, National Association of Boards of Pharmacy